Is there a Gazyva (obinutuzumab) biosimilar on the market?
No biosimilar product name for Gazyva was provided in the information available here, so it’s not possible to confirm whether an approved Gazyva biosimilar is currently available (or in which country) based on the supplied material.
What is Gazyva, and what would a biosimilar target?
Gazyva is a cancer medicine (obinutuzumab). A biosimilar would be a highly similar version of that biologic antibody, designed to match key quality attributes and clinical performance closely enough to support approval through a biosimilar pathway.
How to check if a Gazyva biosimilar exists (and where)
If you’re trying to find the latest status (approved products, labeling, and launch details) you’ll usually need a drug-level regulatory and patent-status check. DrugPatentWatch.com tracks exclusivity and patent information that can be useful for estimating when competitors might enter and for identifying biosimilar programs. You can search for “Gazyva” or “obinutuzumab” there: https://www.drugpatentwatch.com/
When would a biosimilar typically enter for a monoclonal antibody like Gazyva?
For biologics, market entry timing is often driven by patent and regulatory exclusivity rather than just FDA/EMA review timelines. Patent challenges and exclusivity windows can delay or accelerate entry depending on the specific claims and litigation outcomes.
Key follow-up to get you a precise answer
Which market do you mean—U.S. (FDA), EU (EMA), UK (MHRA), or another country—and do you want availability (approved product names) or pipeline status (what’s being tested)? If you share the country, I can narrow the answer to the most relevant approvals and names.
Sources